| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,033 | 0,040 | 23.10. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.09. | LIFECARE ASA: Mandatory Notification of Trade by Primary Insider | 3 | Oslo Børs | ||
| 29.09. | LIFECARE ASA: Lifecare successfully manufactures first functional implants in-house in Bergen | 4 | Oslo Børs | ||
| 15.09. | Lifecare ASA: Share capital increase registered | 2 | Oslo Børs | ||
| 31.08. | Lifecare ASA acquires 80% of Ocean TuniCell securing established GMP manufacturing infrastructure in Bergen | 4 | Oslo Børs | ||
| 31.08. | OCEAN GEOLOOP ASA: Captured AS enters into agreement to sell its shares in its subsidiary Ocean Tunicell AS to Lifecare ASA | 2 | Oslo Børs | ||
| 19.08. | LIFE: Lifecare ASA Q2 2026 results | 4 | Oslo Børs | ||
| 12.08. | Lifecare ASA (LIFE): Invitation to presentation of Q2 2026 results 19 August at 08.45 CEST | 1 | Oslo Børs | ||
| 02.07. | Lifecare ASA: LIFE: Update on production transfer and longevity programme | 2 | Oslo Børs | ||
| LIFECARE ASA Aktie jetzt für 0€ handeln | |||||
| 26.06. | Lifecare ASA: LIFE: Operational update regarding Lifecare Germany GmbH (i.L) | 4 | Oslo Børs | ||
| 22.06. | Lifecare ASA: Share capital increase registered | 6 | Oslo Børs | ||
| 22.06. | Lifecare ASA: LIFE: Independent tissue analysis confirms no adverse tissue response after six months of implantation | 3 | Oslo Børs | ||
| 12.06. | Lifecare ASA: Final results following expiry of exercise period for Warrants Series 2 issued in connection with Rights Issue | 6 | Oslo Børs | ||
| 12.06. | Lifecare ASA: Last day of the Exercise Period for Warrants Series 2 issued in connection with the Rights Issue | 3 | Oslo Børs | ||
| 10.06. | Lifecare ASA: Mandatory notification of trade | 2 | Oslo Børs | ||
| 10.06. | Lifecare ASA: Lifecare completes first six-month implant evaluation with continued functionality and no adverse biological response | 1 | Oslo Børs | ||
| 05.06. | Lifecare ASA: Last day of trading in Warrants Series 2 issued in connection with the Rights Issue | 2 | Oslo Børs | ||
| 03.06. | Lifecare ASA: Mandatory notification of trade | 1 | Oslo Børs | ||
| 01.06. | Lifecare ASA: Commencement of the Exercise Period for Warrants Series 2 issued in connection with the Rights Issue | 2 | Oslo Børs | ||
| 29.05. | Lifecare ASA: Exercise price for Warrants Series 2 issued in connection with the Rights Issue | - | Oslo Børs | ||
| 15.05. | LIFE: Lifecare ASA Q1 2026 results | 3 | Oslo Børs |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,070 | -4,88 % | Sernova Biotherapeutics mit EILMELDUNG: Könnte die Aktie nach 33,3 % Plus jetzt komplett durchstarten? - Handeln Sie, bevor es zu spät ist! | ||
| BOSTON SCIENTIFIC | 40,900 | +0,26 % | TD Cowen reiterates Boston Scientific stock rating on 2027 outlook | ||
| PAUL HARTMANN | 191,50 | -1,03 % | Januar bis Juni 2026: PAUL HARTMANN steigert erneut Umsatz und Ergebnis | Heidenheim (ots) - - Erfolgreiches 1. Halbjahr: Umsatzerlöse steigen auf 1.252,0 Mio. EUR, organisches Umsatzwachstum von 3,3 %; bereinigtes EBITDA liegt mit 151,7 Mio. EUR um 25,9 Mio. EUR über Vorjahreswert-... ► Artikel lesen | |
| SYSMEX | 10,800 | -2,09 % | Dividendenbekanntmachungen (29.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 77 BANK LTD JP3352000008 52 JPY 0,2906 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1799 EUR ACOM CO LTD JP3108600002 11 JPY 0... ► Artikel lesen | |
| ADDLIFE | 16,320 | 0,00 % | AddLife Q3 2026 slides: profit surges 61% on margin gains, M&A ramps up | ||
| EMBECTA | 5,982 | -0,13 % | Dividendenbekanntmachungen (27.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADDTECH AB SE0014781795 3,6 SEK 0,3243 EUR ALLIANCE WITAN PLC GB00B11V7W98 0,0733 GBP 0,0855 EUR ATMUS FILTRATION TECHNOLOGIES... ► Artikel lesen | |
| ENOVIS | 19,300 | +2,12 % | Enovis Corporation: Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics | Enhances Enovis' enabling technology ecosystem to include robotic automation capabilities, empowering surgeons with a broader, integrated set of precision tools in the operating room, Creates a robotics... ► Artikel lesen | |
| PULMONX | 1,640 | +6,49 % | Pulmonx Corporation: Pulmonx Reports Second Quarter 2026 Financial Results | REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported... ► Artikel lesen | |
| SI-BONE | 18,700 | +3,31 % | SI-BONE, Inc.: SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026 | ||
| PEIJIA MEDICAL | 0,434 | +4,83 % | Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth | SUZHOU, China, Aug. 24, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and... ► Artikel lesen | |
| KOOTH | 2,160 | 0,00 % | Kooth PLC - Director / PDMR & PCA Dealing | ||
| BACTIGUARD | 1,270 | +10,92 % | Bactiguard Holding AB: Bactiguard Holding AB's interim report third quarter 2026 | Accelerating performance validates our partnership model
Third quarter 2026 (July - September)Total revenue amounted to SEK 58.4 (48.4) million, an increase of SEK 10.0 million corresponding to 20.6%.Net... ► Artikel lesen | |
| SCIBASE | 1,095 | -2,23 % | SciBase has secured first US payer coverage with major insurance company, aims for global lead in non-invasive skin assessment | SciBase has secured first US payer coverage with major insurance company, aims for global lead in non-invasive skin assessmentSTOCKHOLM, Oct. 15, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase")... ► Artikel lesen | |
| PHC HOLDINGS | 7,100 | -2,74 % | Toho Holdings decides to end its review of a possible PHC Holdings acquisition | ||
| FRESENIUS | 46,100 | +1,75 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - JPMorgan hat Fresenius nach Gesprächen mit der Investor-Relations-Abteilung mit einem Kursziel von 55,20 Euro auf "Overweight" belassen. Die Aktien stehen zudem auf der... ► Artikel lesen |